{"id":"https://openalex.org/W2885586780","doi":"https://doi.org/10.1158/1538-7445.am2018-4958","title":"Abstract 4958: VTP50469 is a novel, orally available menin-MLL1 inhibitor effective against MLL-rearranged and NPM1-mutant leukemia","display_name":"Abstract 4958: VTP50469 is a novel, orally available menin-MLL1 inhibitor effective against MLL-rearranged and NPM1-mutant leukemia","publication_year":2018,"publication_date":"2018-07-01","ids":{"openalex":"https://openalex.org/W2885586780","doi":"https://doi.org/10.1158/1538-7445.am2018-4958","mag":"2885586780"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2018-4958","doi":"https://doi.org/10.1158/1538-7445.am2018-4958","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2018-4958","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016322483","display_name":"Andrei V. Krivtsov","orcid":"https://orcid.org/0000-0002-5511-1686","observed_orcids":["https://orcid.org/0000-0002-5511-1686"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrei V. Krivtsov","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026113696","display_name":"Benjamin K. Eschle","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Benjamin K. Eschle","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004965064","display_name":"Matthew D. Witkin","orcid":"https://orcid.org/0000-0002-6593-8468","observed_orcids":["https://orcid.org/0000-0002-6593-8468"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew Witkin","raw_affiliation_strings":["2Memorial Sloan Kettering Cancer Center, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Memorial Sloan Kettering Cancer Center, New York, NY;","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038246149","display_name":"Jayant Y. Gadrey","orcid":"https://orcid.org/0000-0001-7749-7703","observed_orcids":["https://orcid.org/0000-0001-7749-7703"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jayant Y. Gadrey","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029398334","display_name":"Hannah J. Uckelmann","orcid":"https://orcid.org/0000-0003-2048-7357","observed_orcids":["https://orcid.org/0000-0003-2048-7357"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hannah J. Uckelmann","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032450703","display_name":"Sayuri Kitajima","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sayuri Kitajima","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025042977","display_name":"Gerard M. McGeehan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405271706","display_name":"Syndax Pharmaceuticals (United States)","ror":"https://ror.org/02w9kv048","country_code":"US","type":"company","lineage":["https://openalex.org/I4405271706"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gerard M. McGeehan","raw_affiliation_strings":["3Syndax Pharmaceuticals, Inc., Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Syndax Pharmaceuticals, Inc., Waltham, MA","institution_ids":["https://openalex.org/I4405271706"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5012956545","display_name":"Scott A. Armstrong","orcid":"https://orcid.org/0000-0002-9099-4728","observed_orcids":["https://orcid.org/0000-0002-9099-4728"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott A. Armstrong","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"78","issue":"13_Supplement","first_page":"4958","last_page":"4958"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.0019000000320374966,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/menin","display_name":"menin","score":0.718999981880188},{"id":"https://openalex.org/keywords/mll1","display_name":"MLL1","score":0.9139999747276306},{"id":"https://openalex.org/keywords/mll-rearranged-acute-myeloid-leukemia","display_name":"MLL-rearranged acute myeloid leukemia","score":0.8479999899864197},{"id":"https://openalex.org/keywords/mll-fusion-proteins","display_name":"MLL fusion proteins","score":0.859000027179718},{"id":"https://openalex.org/keywords/mll-af9","display_name":"MLL-AF9","score":0.7450000047683716},{"id":"https://openalex.org/keywords/mll-af4","display_name":"MLL-AF4","score":0.9380000233650208},{"id":"https://openalex.org/keywords/b-cell-acute-lymphoblastic-leukemia","display_name":"B-cell acute lymphoblastic leukemia","score":0.7440000176429749},{"id":"https://openalex.org/keywords/oral-small-molecule-inhibitor","display_name":"oral small-molecule inhibitor","score":0.7160000205039978},{"id":"https://openalex.org/keywords/structure-based-drug-design","display_name":"structure-based drug design","score":0.8339999914169312},{"id":"https://openalex.org/keywords/patient-derived-xenografts","display_name":"patient-derived xenografts","score":0.48899999260902405},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.5649999976158142}],"concepts":[{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5699342489242554},{"id":"https://openalex.org/C143065580","wikidata":"https://www.wikidata.org/wiki/Q3285695","display_name":"Mutant","level":3,"score":0.5678057670593262},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5533612966537476},{"id":"https://openalex.org/C2778502085","wikidata":"https://www.wikidata.org/wiki/Q7662767","display_name":"Synthetic lethality","level":4,"score":0.46687787771224976},{"id":"https://openalex.org/C111829193","wikidata":"https://www.wikidata.org/wiki/Q1108970","display_name":"Fusion gene","level":3,"score":0.4298252463340759},{"id":"https://openalex.org/C123894998","wikidata":"https://www.wikidata.org/wiki/Q425158","display_name":"Fusion protein","level":4,"score":0.41899266839027405},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.3887408673763275},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.24468591809272766},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.16270223259925842},{"id":"https://openalex.org/C40767141","wikidata":"https://www.wikidata.org/wiki/Q285697","display_name":"Recombinant DNA","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2018-4958","doi":"https://doi.org/10.1158/1538-7445.am2018-4958","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2018-4958","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2993435749","https://openalex.org/W4282938078","https://openalex.org/W4393085664","https://openalex.org/W2885882527","https://openalex.org/W4242135586","https://openalex.org/W2741755572","https://openalex.org/W3204213484","https://openalex.org/W4409645183","https://openalex.org/W4205640844","https://openalex.org/W4282965965"],"abstract_inverted_index":{"Abstract":[0],"Inhibition":[1],"of":[2,31,66,93,97,136,150,193,223,242,296,332,338,345,400,414,462],"the":[3,67,98,401,463],"menin(MEN)":[4],"and":[5,16,44,52,56,75,116,140,181,200,203,226,252,270,288,304,320,336,347,350,375,417,456],"MLL1(KMT2A)":[6],"interaction":[7,33,403],"reverses":[8],"leukemic":[9],"gene":[10,206,342],"expression":[11,192,207,331],"driven":[12,80],"by":[13,81,158,175],"MLL-fusion":[14,82,195,340],"proteins":[15,83],"is":[17,446],"a":[18,62,385,447],"potential":[19],"targeted":[20],"therapeutic":[21],"strategy":[22],"in":[23,38,54,57,152,166,169,177,198,208,239,247,250,254,262,300,315,318,322,410],"MLL-rearranged":[24,224,284,286,455],"AML.":[25,40],"Recent":[26],"data":[27],"show":[28],"that":[29,48],"inhibition":[30,399],"this":[32,276],"could":[34],"also":[35,204],"be":[36],"efficacious":[37],"NPM1-mutant":[39,137,209,289,457],"We":[41],"developed":[42],"potent":[43,63],"selective":[45,51],"menin-MLL1":[46,68,362,402,451],"inhibitors":[47],"are":[49],"highly":[50,125,386],"effective":[53,387,453],"vitro":[55],"vivo.":[58],"Structure-based":[59],"design":[60],"yielded":[61],"small-molecule":[64],"inhibitor":[65,99,452],"binding":[69],"interaction,":[70],"VTP-49477":[71,91,219,231],"(Ki=12+5":[72],"pM).":[73,109],"Human":[74,212],"mouse":[76,117,263],"leukemia":[77,210,243,298,358,458],"cell":[78,114],"lines":[79,115],"or":[84,122,189,220],"NPM1":[85],"mutations":[86],"were":[87,124,215,273],"selectively":[88],"sensitive":[89,126],"to":[90,102,111,127,309,412],"(IC50":[92,131],"~10":[94],"nM).":[95,133],"Optimization":[96],"structure":[100],"led":[101],"an":[103],"orally":[104,449],"available":[105,450],"inhibitor,":[106],"VTP-50469":[107,130,146,163,259,354,361,367,389,405],"(Ki=104+30":[108],"Similar":[110],"VTP-49477,":[112],"human":[113,297,415],"primary":[118],"cells":[119,139,144,202,299,325],"carrying":[120],"MLL-fusions":[121],"NPM1c-mutations":[123],"treatment":[128,135,164,185],"with":[129,145,186,217,230,275,283,329,353,366,404],"~20":[132],"Mechanistically,":[134],"OCI-AML3":[138],"MLL-AF9":[141],"rearranged":[142,179],"MOLM13":[143,182,201],"caused":[147],">20-fold":[148],"reduction":[149,168,241],"menin":[151,170],"high-molecular-weight":[153],"protein":[154],"complexes":[155],"as":[156,173,307],"assessed":[157,174],"glycerol":[159],"gradient":[160],"sedimentation.":[161],"Concordantly,":[162],"resulted":[165,238],">10-fold":[167],"chromatin":[171],"occupancy":[172],"ChIP-seq":[176],"MLL-AF4":[178],"RS4;11":[180,199],"cells.":[183,211],"Furthermore,":[184],"either":[187,218],"VTP50469":[188,445],"VTP4777":[190],"reduced":[191],"common":[194,339],"target":[196,341,363],"genes":[197],"modulated":[205],"PDX":[213,271],"models":[214,272],"treated":[216,274,311],"VTP-50469.":[221],"Treatment":[222,344,365],"B-ALL":[225,349],"AML":[227,287,290,324,351,416],"PDXs":[228,291,352],"(n=3)":[229],"for":[232,278,466],"28":[233,279],"days":[234],"(50mg/kg,":[235],"bid,":[236],"IP)":[237],"significant":[240],"burden":[244],"(median:":[245,313],"2-fold":[246],"BM,":[248,316],"3-fold":[249],"SP,":[251],"6-fold":[253],"PB).":[255,323],"For":[256],"oral":[257],"dosing,":[258],"was":[260,379],"formulated":[261],"chow":[264,277],"(0.1%,":[265],"total":[266],"daily":[267],"dose":[268],"~175mg/kg/day)":[269],"days.":[280],"Mice":[281],"engrafted":[282],"B-ALL,":[285],"(n=5)":[292],"showed":[293,326],"dramatic":[294],"reductions":[295],"peripheral":[301,372],"blood,":[302],"spleen":[303],"bone":[305],"marrow":[306],"compared":[308],"control":[310],"mice":[312],"225-fold":[314],"14-fold":[317],"SP":[319],"129-fold":[321],"increased":[327],"differentiation":[328],"elevated":[330],"CD11b,":[333],"CD13,":[334],"CD86":[335],"loss":[337,378],"expression.":[343],"MLL1wt":[346],"NPM1wt":[348],"did":[355,368],"not":[356,369,391],"reduce":[357],"burden,":[359],"confirming":[360],"selectivity.":[364],"alter":[370],"normal":[371],"blood":[373],"counts":[374],"no":[376],"weight":[377],"observed":[380],"during":[381],"treatment.":[382],"Therefore,":[383],"at":[384],"dose,":[388],"does":[390],"have":[392,407],"detectable":[393],"toxicity.":[394],"Based":[395],"on":[396],"these":[397],"data,":[398],"may":[406],"beneficial":[408],"activity":[409],"up":[411],"40%":[413],"most":[418],"infant":[419],"leukemias.":[420],"Citation":[421],"Format:":[422],"Andrei":[423],"V.":[424],"Krivtsov,":[425],"Benjamin":[426],"K.":[427],"Eschle,":[428],"Matthew":[429],"Witkin,":[430],"Jayant":[431],"Y.":[432],"Gadrey,":[433],"Hannah":[434],"J.":[435],"Uckelmann,":[436],"Sayuri":[437],"Kitajima,":[438],"Gerard":[439],"M.":[440],"McGeehan,":[441],"Scott":[442],"A.":[443],"Armstrong.":[444],"novel,":[448],"against":[454],"[abstract].":[459],"In:":[460],"Proceedings":[461],"American":[464],"Association":[465],"Cancer":[467,480],"Research":[468],"Annual":[469],"Meeting":[470],"2018;":[471],"2018":[472],"Apr":[473],"14-18;":[474],"Chicago,":[475],"IL.":[476],"Philadelphia":[477],"(PA):":[478],"AACR;":[479],"Res":[481],"2018;78(13":[482],"Suppl):Abstract":[483],"nr":[484],"4958.":[485]},"counts_by_year":[{"year":2020,"cited_by_count":1}],"updated_date":"2026-09-21T07:43:02.447757","created_date":"2018-08-22T00:00:00"}